PO.BCS01.04 · 生物信息与计算

通过多组学识别胰腺导管腺癌中的分子特征

Identification of molecular signatures in pancreatic ductal adenocarcinoma through multiomics

海报缩略图:通过多组学识别胰腺导管腺癌中的分子特征
编号 4122 展板 2 时间 4/21 09:00–12:00 区域 Section 2 主讲 Benjamin Miao
分会场 Application of Bioinformatics to Cancer Biology 4
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Benjamin Miao1, Tung-Shing Mamie Lih2, Yingwei Hu2, Hui Zhang2

1Johns Hopkins Univeristy, Baltimore, MD,2Johns Hopkins University School of Medicine, Baltimore, MD

摘要 Abstract

中文摘要
胰腺导管腺癌(PDAC)是最致命的恶性肿瘤之一,五年生存率极低。尽管人们持续努力研究其分子特征,但PDAC中高度的肿瘤相关细胞异质性引入了外源性微环境成分,使分析复杂化。近年来,多组学方法在解卷积细胞组成以及实现更具特异性、更全面的癌症分析方面展现出前景。为更好地表征PDAC,本研究分析了来自140例肿瘤组织及67例配对癌旁正常组织的转录组和蛋白质组数据,以及来自73例肿瘤组织的单细胞RNA测序数据。利用这一整合方法,我们成功地将分子特征归因于不同的细胞类型群体。总体而言,我们发现了59个肿瘤细胞来源的PDAC分子特征,并评估了它们的功能相关性、预后价值和潜在治疗意义。其中,我们识别出与肿瘤发生活性增强和免疫抑制相关的分子靶点。此外,对蛋白磷酸化和整体表达的生存分析为潜在靶点提供了预后意义信息。值得注意的是,我们发现若干磷酸化改变与患者不良生存相关,提示通过靶向蛋白翻译后修饰进行治疗干预的潜在途径。我们的研究通过表征可作为潜在靶点的关键肿瘤特异性特征,提供了对PDAC的详细理解,有助于改善该疾病的临床结局。
查看英文原文 English abstract
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest malignancies, with a dismal five-year survival rate. Despite continuous efforts to study its molecular signatures, the high degree of tumor-associated cellular heterogeneity in PDAC introduces extraneous microenvironmental components that complicate analysis. In recent years, multi-omics approaches have shown promise in deconvoluting cellular composition and enabling more specific, comprehensive cancer profiling. To better characterize PDAC, in this study, we analyzed transcriptomic and proteomic data from 140 tumor tissues with 67 paired normal adjacent tissues, along with single-cell RNA sequencing data from 73 tumor tissues. Using this integrative approach, we successfully attributed molecular signatures to distinct cell-type populations. Overall, we found 59 tumor-cell derived PDAC molecular signatures and evaluated them for functional relevance, prognostic value, and potential therapeutic implications. Among these, we identified molecular targets associated with increased tumorigenic activity and immunosuppression. Moreover, survival analysis of protein phosphorylation and overall expression informed prognostic significance for potential targets. Notably, we found that several phosphorylation changes correlate with poor patient survival, suggesting potential paths for therapeutic intervention by targeting protein post-translational modifications. Our study provides a detailed understanding of PDAC through characterization of key tumor-specific signatures that could serve as potential targets to help improve clinical outcomes for this disease. 
利益披露 Disclosure
B. Miao, None.. Y. Hu, None.. H. Zhang, None.

← 返回 AACR 2026 检索